Sloan-kettering Institute for Cancer Research

Pfizer Corporation

Cytomed, Inc.

Karl Henry Nocka

Jochen Buck

Peter Besmer

Malcolm A Moore

James Reasoner Apgar

Malcolm A S Moore

Laird Bloom

Matthew Allister Lambert

Robert B Lobell

Mark A Farmer

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to IL-33, as well as uses, and associated methods thereof.

Anti-IL-33 antibodies, compositions, methods and uses thereof

A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.

C-kit ligand-based method for expanding peripheral blood cell levels

Compositions comprising c-kit ligand, TNF-.alpha., and a hematopoietic factor are useful to promote the expansion of peripheral blood cells or the expansion and differentiation of hematopoietic progenitor cells.

Use of c-kit ligand with TNF-.alpha. and hematopoietic factors for the

Composition of c-kit ligand, GM-CSF, and TNF-.alpha. and method of use

Method for increasing the level of stem cells in peripheral blood

Compositions of soluble C-kit ligand and hematopoietic factors

A modified form of KL, the ligand for the c-Kit proto-oncogene, has been prepared wherein the protein is stabilized by an intermolecular covalent linkage. The protein can be prepared by expression of a recombinant protein which is dissolved in denaturant and refolded under conditions resulting in a disulfide linked dimer. Examples demonstrate the purification and characterization of this disulfide-linked cysteine dimer kit ligand (KL-CD) which contains at least one intermolecular disulfide bond and has at least ten-fold greater activity in promoting cell proliferation than native, non-covalently linked KL, as measured in in vitro assays.

Covalent dimer of kit ligand

Growing community of inventors

Harvard, MA, United States of America

Karl Henry Nocka